Boston Scientific Acquires Silk Road Medical for $27.50 per Share

June 18, 2024

Boston Scientific Corporation agreed to acquire Silk Road Medical, Inc. for $27.50 per share in an all-cash transaction valuing Silk Road's equity at approximately $1.26 billion. The acquisition brings Silk Road's TransCarotid Artery Revascularization (TCAR) platform into Boston Scientific's vascular portfolio to expand treatment options for carotid artery disease and strengthen the company's vascular technology offerings.

Buyers
Boston Scientific Corporation
Targets
Silk Road Medical, Inc.
Sellers
Silk Road Medical stockholders
Industry
Medical Devices
Location
California, United States
Transaction Type
Buyout

Explore More

Related Acquisitions

Track M&A activity that matters to you

Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.